Loading...
OTCM
ATRX
Market cap0kUSD
Oct 07, Last price  
0.00USD
Name

Adhera Therapeutics Inc

Chart & performance

D1W1MN
OTCM:ATRX chart
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
36.23%
Rev. gr., 5y
76.78%
Revenues
0
19,440,0001,847,0007,449,00028,490,00018,137,0002,609,00014,732,0002,460,0002,236,0004,217,0002,115,000500,000680,0000076,186252,000000
Net income
-2m
L-66.71%
-2,141,000-28,609,000-32,163,000-26,877,000-52,372,000-59,220,000-8,046,000-27,753,000-29,424,000-9,546,000-1,571,000-6,477,0003,337,000-837,000-6,219,000-16,755,000-11,978,000-3,766,000-6,351,000-2,114,000
CFO
-1m
L+112.78%
-7,686,000-19,168,000-31,279,000-14,753,000-46,463,000-40,474,000-7,525,000-16,801,000-16,117,000-4,391,000285,000-4,779,000-2,165,000-522,314-1,260,685-9,611,433-8,738,000-588,000-665,000-1,415,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson’s disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.

Key people

Mihir Munsif
Chief Operating Officer · since 2017
Larn Hwang
Chief Scientific Officer · since 2017
Peter D. Weinstein
Chief Legal Officer · since 2017
Isaac Blech
Director · since 2017
Erik Emerson
Director · since 2019
Nancy R. Phelan
Chief Executive Officer, Director · since 2019
Philip C. Ranker
Director · since 2013
URL
https://adherathera.com/
IPO date
Apr 15, 1994
Employees
2
Domiciled in
US
Incorporated in
US
Legal address
C/O LEGALINC CORPORATE SERVICES INC.
131 CONTINENTAL DRIVE
SUITE 305
NEWARK, DE 19713
US
Headquarters
17870 Castleton Street
Suite 250
City of Industry
Los Angeles, CA 91748
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT